Boston Scientific’s Acurate Neo2 Aortic Valve System Evaluated in European Postmarket Study
November 27, 2022—Boston Scientific Corporation announced the first results from the Acurate Neo2 postmarket clinical follow-up (PMCF) study evaluating the performance of the company’s Acurate Neo2 aortic valve system.
